Aclarion, Inc. - ACON STOCK NEWS

Aclarion, a healthcare technology company focused on chronic low back pain, announced significant findings from a clinical trial involving 78 patients. The trial demonstrated an 85% success rate for surgeries targeting discs identified by Nociscan, marking a 22 percentage point improvement over treatments not aligned with Nociscan results (85% vs. 63%; p=0.07). Nociscan, an augmented intelligence platform, measures pain biomarkers without invasive procedures like discography. This two-year durability data, published in the European Spine Journal, emphasizes the platform's potential to aid physicians in optimizing treatment strategies. Aclarion plans to continue clinical trials to further validate these findings and present additional economic benefits at upcoming conferences.

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the appointment of Dr. Alpesh Patel as a key opinion leader (KOL) to enhance its chronic low back pain (CLBP) solution, Nociscan. This marks the eighth advisor in Aclarion's KOL program aimed at strengthening clinical evidence for US commercialization. Nociscan leverages biomarkers and augmented intelligence to assist physicians in identifying pain sources in lumbar discs. Dr. Patel's expertise in spine care is expected to drive significant insights for Aclarion while participating in SPINEWEEK 2023 from May 1-5, 2023.

Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology firm, is set to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference from February 21-24, 2023. Jeff Thramann, Executive Chairman, will present on February 21 at 11:30 AM ET. The conference will feature 37 top companies selected by qualified institutional investors. Aclarion leverages biomarkers and augmented intelligence to identify chronic low back pain and has developed Nociscan, a SaaS platform that helps physicians distinguish between painful and nonpainful discs. For more details, visit www.aclarion.com.

Aclarion, a healthcare tech company focusing on chronic low back pain (CLBP), announced its participation in the 2nd Annual Sonntag Spine Symposium on February 17, 2023. Aclarion's flagship product, Nociscan, is the first SaaS platform that objectively measures discogenic biomarkers to aid in diagnosing CLBP. This innovative tool helps distinguish between painful and nonpainful discs, providing critical insights for treatment strategies. With over 266 million people affected by generative spine disease globally, Nociscan aims to optimize clinical outcomes through enhanced decision support for physicians.

Aclarion, a healthcare technology company listed on Nasdaq under ACON and ACONW, has appointed Dr. Gregory Basil from the University of Miami as a key opinion leader. Dr. Basil, a renowned spine surgeon, aims to enhance clinical outcomes through Aclarion's innovative Nociscan platform, which identifies chronic low back pain sources via biomarkers. This SaaS solution allows physicians to differentiate between painful and nonpainful lumbar discs, offering critical insights for optimized treatment strategies. Dr. Basil is the seventh advisor to join Aclarion's clinical evidence team, reinforcing its commitment to improving patient care.

Aclarion, Inc. (Nasdaq: ACON, ACONW) has appointed George Frey, MD, as a key opinion leader to guide its innovative Nociscan solution for chronic low back pain (cLBP). Dr. Frey, founder of the Colorado Comprehensive Spine Institute, has extensive experience in medical device invention and patents. Aclarion's Nociscan platform uses biomarkers and algorithms to identify painful lumbar discs, addressing a major healthcare challenge. As cLBP significantly contributes to opioid addiction and healthcare costs, the company's advancements offer a new approach. Aclarion aims to leverage Dr. Frey's expertise to enhance its strategy and expand its KOL program into 2023.

Aclarion, a healthcare technology company, has appointed Dr. Christopher Ames as a Key Opinion Leader to enhance its Nociscan solution for chronic low back pain (cLBP). This SaaS platform is the first evidence-supported tool that helps physicians differentiate between painful and nonpainful discs in the lumbar spine. Dr. Ames emphasizes that the Nociscan tool will improve diagnostic clarity and patient outcomes. Additionally, Aclarion's Nociscan is included in a pivotal NIH-funded trial and has recently secured a new patent addressing painful disc degeneration.

Aclarion, a healthcare technology company, has appointed Dr. Eric Potts as a key opinion leader. Dr. Potts, a neurosurgeon, will assist in promoting Aclarion's Nociscan solution, which helps physicians identify chronic low back pain. Nociscan is the first SaaS platform to noninvasively distinguish between painful and nonpainful discs, leveraging chemical biomarkers. Aclarion aims to strengthen its clinical evidence and market support for this innovative approach, enhancing treatment strategies while addressing a major healthcare issue.

Aclarion, Inc. (ACON, ACONW) announced the appointment of Dr. Juan Uribe as a key opinion leader to enhance its efforts in chronic low back pain (cLBP) diagnostics. Dr. Uribe, renowned in spinal disorder research, will support Aclarion's objective of integrating clinical evidence and securing payer advocacy. The company's flagship Nociscan platform noninvasively identifies painful versus nonpainful lumbar discs using advanced biomarkers and algorithms. Aclarion aims to improve diagnostic accuracy and treatment strategies for cLBP, a leading cause of opioid addiction in the U.S.